# Differentiation syndrome on IDH, FLT3 and menin inhibitors and on tretinoin or arsenic trioxide: recognition and treatment

Source: https://onco.cc/protocols/differentiation-syndrome-recognition-and-treatment/  
OnCo record `differentiation-syndrome-recognition-and-treatment` (Protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Some leukaemia medicines work by making leukaemia cells mature. This can cause fever, breathlessness, fluid on the lungs, sudden weight gain, swelling, low blood pressure or kidney problems. This is differentiation syndrome. It is treated at once with a steroid such as dexamethasone and can be fatal if not treated. Call your team or go to the nearest emergency department right away.

## Summary

Differentiation syndrome follows any drug that pushes myeloid blasts to mature: tretinoin and arsenic trioxide in acute promyelocytic leukaemia (APL), the IDH inhibitors ivosidenib, enasidenib and olutasidenib, the FLT3 inhibitor gilteritinib and the menin inhibitors revumenib and ziftomenib. All eight US labels carry a boxed warning. There is no diagnostic test. The PETHEMA criteria (two or more of dyspnoea, unexplained fever, weight gain above 5 kg, unexplained hypotension, acute renal failure, and pulmonary infiltrates or pleuropericardial effusion on imaging) were written for APL and were used by the FDA to re-read the ivosidenib and enasidenib trials, where they found the syndrome in 19% of patients on each drug against 11 to 14% reported, with a median onset of 20 and 19 days and leukocytosis present in 79% and 61% of cases, so not in all.

Timing differs by class. In APL the median onset is 7 to 12 days with two peaks, in the first and third weeks. On IDH inhibitors it can start from day 1 and as late as 3 months (ivosidenib), 5 months (enasidenib) or 18 months (olutasidenib); on gilteritinib from day 1 to day 82; on revumenib a median of 9 days (range 3 to 41); on ziftomenib a median of 15 days (range 3 to 46).

The core of treatment is consistent across the sources: dexamethasone 10 mg every 12 hours started on suspicion (the labels and the ELN APL panel), without waiting for an abnormal chest radiograph (PETHEMA review), with haemodynamic monitoring (the labels). Seven of the eight labels set a minimum of 3 days of steroids; enasidenib's gives no minimum and says to taper only after symptoms resolve, and the ELN panel says steroids can be discontinued once the syndrome has resolved. Hydroxyurea for accompanying leukocytosis is on every label except gilteritinib's, which gives no rule for leukocytosis (the tretinoin label says to consider cytoreductive chemotherapy, including hydroxyurea). Leukapheresis 'if clinically indicated' is on the ivosidenib, revumenib and ziftomenib labels only, and is to be avoided in APL (ELN III-B). The FDA authors say empirical antibiotics are equally important to consider, because infection and the syndrome share signs and can be present together. The sources differ on when to stop the causative drug (at once on olutasidenib, ziftomenib and arsenic trioxide; only if severe signs persist beyond 48 hours of steroids on ivosidenib, gilteritinib and revumenib; only for severe syndrome in the ELN APL recommendations) and on steroid prophylaxis in APL (for adults with newly diagnosed low-risk APL on arsenic trioxide with tretinoin in the US label; optional and of uncertain value, by white count, in the ELN recommendations). The reader's own team's protocol comes first.

## Fields

- Kind: Protocol
- Last checked: 2026-11-17
- Also known as: differentiation syndrome; DS; retinoic acid syndrome; ATRA syndrome; IDH differentiation syndrome; IDH-DS; menin inhibitor differentiation syndrome; APL differentiation syndrome; dexamethasone 10 mg twice daily for differentiation syndrome

## Connected records

- protocols: [Capillary leak syndrome on tagraxofusp, dinutuximab, aldesleukin and gemcitabine: monitoring and treatment](https://onco.cc/protocols/capillary-leak-syndrome-on-anticancer-drugs/), [Fluid retention, swelling and pleural effusion on kinase inhibitors and MET-targeted drugs](https://onco.cc/protocols/fluid-retention-and-effusions-on-kinase-inhibitors/), [Hyperleukocytosis and leukostasis in acute leukaemia: supportive care, cytoreduction and leukapheresis](https://onco.cc/protocols/hyperleukocytosis-leukostasis/), [Suspected febrile neutropenia (neutropenic sepsis): the first hour](https://onco.cc/protocols/febrile-neutropenia-first-hour/), [Tumour lysis syndrome: risk assessment, prophylaxis and treatment](https://onco.cc/protocols/tumour-lysis-syndrome-prevention-and-treatment/)
- drugs: [Arsenic trioxide](https://onco.cc/drugs/arsenic-trioxide/), [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Enasidenib](https://onco.cc/drugs/enasidenib/), [Gilteritinib](https://onco.cc/drugs/gilteritinib/), [Hydroxyurea (hydroxycarbamide)](https://onco.cc/drugs/hydroxyurea/), [Ivosidenib](https://onco.cc/drugs/ivosidenib/), [Olutasidenib](https://onco.cc/drugs/olutasidenib/), [Revumenib](https://onco.cc/drugs/revumenib/), [Tretinoin (all-trans retinoic acid, ATRA)](https://onco.cc/drugs/tretinoin-atra/), [Ziftomenib](https://onco.cc/drugs/ziftomenib/)
- terms: [Differentiation syndrome](https://onco.cc/terms/differentiation-syndrome/), [Tumour lysis syndrome (TLS)](https://onco.cc/terms/tumor-lysis-syndrome/)

---
JSON: https://onco.cc/api/v1/entities/differentiation-syndrome-recognition-and-treatment.json